Understanding Critical Congenital Heart Defects

- Congenital heart defects (CHDs) account for nearly 30% of infant deaths due to birth defects.
- In the United States, about 7,200 (or 18 per 10,000) babies born every year have critical congenital heart defects (CCHDs, which also are known collectively in some instances as critical congenital heart disease). These CCHDs are coarctation of the aorta, double-outlet right ventricle, D-transposition of the great arteries, Ebstein anomaly, hypoplastic left heart syndrome, interrupted aortic arch, pulmonary atresia (intact septum), single ventricle, total anomalous pulmonary venous connection, tetralogy of Fallot, tricuspid atresia, and truncus arteriosus.
- Babies with CCHDs usually require surgery or catheter intervention in the first year of life.
- CCHDs can potentially be detected using pulse oximetry screening, which is a test to determine the amount of oxygen in the blood and pulse rate.
- Pulse oximetry screening is most likely to detect seven of the CCHDs. These seven main screening targets are:
  » Hypoplastic left heart syndrome
  » Pulmonary atresia (with intact septum)
  » Tetralogy of Fallot
  » Total anomalous pulmonary venous return
  » Transposition of the great arteries
  » Tricuspid atresia
  » Truncus arteriosus

Other heart defects can be just as severe as the main screening targets and also require treatment soon after birth. However, pulse oximetry screening may not detect these heart defects as consistently as the seven disorders listed as the main screening targets.

The Importance of Screening for Critical Congenital Heart Defects

Some babies born with a heart defect appear healthy at first and can be sent home with their families before their heart defect is detected. It has been estimated that about 300 infants with an unrecognized CCHD are discharged each year from newborn nurseries in the United States. These babies are at risk for having serious complications within the first few days or weeks of life and often require emergency care.

Newborn screening using pulse oximetry can identify some infants with a CCHD before they show signs of a CCHD. Once identified, babies with a CCHD can be seen by cardiologists and can receive specialized care and treatment that could prevent death or disability early in life. Treatment can include medications and surgery.
When and How Babies Are Screened

Pulse oximetry is a simple bedside test to determine the amount of oxygen in a baby’s blood and the baby’s pulse rate. Low levels of oxygen in the blood can be a sign of a CCHD. The test is done using a machine called a pulse oximeter, with sensors placed on the baby’s skin. The test is painless and takes only a few minutes. Screening is done when a baby is 24 to 48 hours of age, or as late as possible if the baby is to be discharged from the hospital before he or she is 24 hours of age.

Pulse oximetry screening does not replace a complete history and physical examination, which sometimes can detect a CCHD before the development of low levels of oxygen in the blood. Pulse oximetry screening, therefore, should be used along with the physical examination.

CCHD Screening Results

If the results are “negative” (“pass” or in-range result), it means that the baby’s test results did not show signs of a CCHD. This type of screening test does not detect all CCHDs, so it is possible to still have a CCHD or other congenital heart defect with a negative screening result. If the results are “positive” (“fail” or out-of-range result), it means that the baby’s test results showed low levels of oxygen in the blood, which can be a sign of a CCHD. This does not always mean that the baby has a CCHD. It just means that more testing is needed.

The baby’s doctor might recommend that the infant get screened again or have more specific tests, like an echocardiogram (an ultrasound picture of the heart), to diagnose a CCHD. Babies who are found to have a CCHD also might be evaluated by a clinical geneticist. This could help identify genetic syndromes associated with CCHDs and inform families about future risks.

Centers for Disease Control and Prevention Activities

The Centers for Disease Control and Prevention (CDC) is part of the U.S. Department of Health and Human Services (HHS) Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC). SACHDNC was authorized by Congress to provide guidance to the HHS Secretary about which conditions should be included in newborn and childhood screening programs, as well as how systems should be developed to ensure that all newborns and children are screened and, when necessary, receive appropriate follow-up care. In September 2010, SACHDNC recommended that the HHS Secretary add screening for CCHDs (i.e., the heart defects listed previously) to the Recommended Uniform Screening Panel. Some states currently are developing their own policies on screening for CCHDs. As this screening is implemented, CDC will play an important role in the surveillance and tracking of babies with a CCHD found through newborn screening.

For more information on screening for CCHDs, please visit
http://www.cdc.gov/ncbddd/pediatricgenetics/CCHDscreening.html